Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Tygerberg, South Africa
Akudugu, J., Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Tygerberg, South Africa; Serafin, A., Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Tygerberg, South Africa; Böhm, L., Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Tygerberg, South Africa
Purpose: To assay for uPA and PAI-1 in prostate tissue from 40 patients with prostatic disease and to examine the robustness of the correlation of the uPA/PAI-1 ratio with benign prostatic hyperplasia (BPH) and prostate cancer (PCa), previously identified in a different cohort of 62 patients.Methods: uPA and PAI-1 were extracted from liquid N<inf>2</inf> frozen homogenised prostate tissue with TRIS/Triton pH 8.5 buffer and measured by ELISA (FEMTELLE).Results: The concentration of uPA (mean ± SD) was found to be 0.1177 ± 0.0266 (range 0.0070–0.7200; n = 30) and 0.1092 ± 0.0130 (range 0.0040–0.7800; n = 70) for PCa and BPH patients, respectively. The concentration of PAI-1 was found to be 5.236 ± 0.688 ng/mg protein (range 1.10–15.19; n = 30) and 4.975 ± 0.501 ng/mg protein (range 0.20–25.00; n = 70) for PCa and BPH patients, respectively. The mean uPA/PAI-1 ratio was found to be 0.0479 ± 0.0060 (range 0.0043–0.1200; n = 30) in PCa samples and was significantly higher than BPH samples where the ratio was 0.0332 ± 0.0023 (range 0.0040–0.0860; n = 70) (P = 0.0064). In PCa patients older than 68 years, the uPA/PAI-1 ratio was above 0.050 reaching 0.100 in 73-year-old patients.Conclusions: Evaluation of 100 patients with prostatic pathologies (70 PCa; 30 BPH) shows the uPA/PAI-1 ratios in PCa patients to be significantly higher than in BPH patients. This is fully consistent with a previous study on 62 patients (16 were PCa; 46 BPH) where the ratios were 0.055 and 0.031 for PCa and BPH patients, respectively (P = 0.0028). In older PCa patients, uPA/PAI-1 ratios tend to be higher. © 2014, Springer-Verlag Berlin Heidelberg.
plasminogen activator inhibitor 1; urokinase; biological marker; plasminogen activator inhibitor 1; urokinase; adult; aged; Article; cancer patient; clinical evaluation; cohort analysis; correlational study; enzyme linked immunosorbent assay; human; human tissue; major clinical study; male; middle aged; pH; priority journal; prostate cancer; prostate hypertrophy; very elderly; age; differential diagnosis; metabolism; Prostatic Hyperplasia; Prostatic Neoplasms; sensitivity and specificity; Age Factors; Aged; Aged, 80 and over; Biological Markers; Diagnosis, Differential; Enzyme-Linked Immunosorbent Assay; Humans; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prostatic Hyperplasia; Prostatic Neoplasms; Sensitivity and Specificity; Urokinase-Type Plasminogen Activator
CANSA, National Research Foundation; 85703, National Research Foundation; 92741, National Research Foundation